Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Government Provides MDx Firm Xagenic with $977K

NEW YORK (GenomeWeb News) – Startup molecular diagnostics company Xagenic today announced funding of up to C$990,000 (US$977,495) from the Canadian government in support of its diagnostic platform.

The funding from the Federal Economic Development Agency for Southern Ontario complements the Toronto-based firm's C$10 million Series A round last year, Xagenic Chief Technology Officer Shana Kelley said, and will be used to support the design and development of the firm's molecular diagnostic platform with a 20-minute time to result.

Xagenic was spun out of the University of Toronto in 2010 and its platform is being developed for use in physician offices, clinics, and hospital systems. The technology uses nanostructured microelectrodes to create nucleic acid sensors to detect DNA and RNA

"In the current environment, financial support from the government enhances our capabilities to develop cutting edge technologies that improve patient care," Xagenic Director of Business Development Ihor Boszko said in a statement.

In 2011, the company received C$1 million from the Ontario Ministry of Research and Innovation to commercialize its microarray-based technology.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.